Antimalarial Drug Development and Resistance Mechanisms

The discovery and refinement of antimalarial therapies has been marked by successive breakthroughs, from cinchona‐derived quinine to synthetic drugs such as chloroquine and, more recently, artemisinin and its derivatives. Combination regimens, especially artemisinin‐based combination therapies (ACTs), have underpinned dramatic reductions in morbidity and mortality by pairing a fast-acting agent with a longer-lived partner drug. Despite these gains, the relentless evolution of Plasmodium spp. parasites has given rise to resistance through diverse mechanisms: point mutations in key genes, gene amplification of drug targets or transporters, altered metabolic pathways and transient quiescent forms. These adaptations compromise drug efficacy and threaten the sustainability of current regimens. In response, researchers are exploring novel chemical scaffolds that target parasite organelles or essential enzymes, optimising pharmacokinetic profiles for single-dose cures, and deploying chemical proteomics to unveil hidden drug–target interactions. High-throughput genetic screens and whole-genome sequencing now allow real-time surveillance of resistance markers, guiding policy on drug rotation and combination design. Integrating molecular insights with clinical pharmacology and socioeconomic considerations remains crucial to sustain global antimalarial control and to move incrementally towards elimination.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antimalarial Drug Development and Resistance Mechanisms publication trend

The graph below shows the total number of articles in antimalarial drug development and resistance mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Artemisinin-based combination therapy (ACT): A treatment combining an artemisinin derivative with a longer-lived partner drug to enhance efficacy and delay resistance.

Genetic mutation: A change in parasite DNA sequence that may alter drug target binding or enzyme function leading to reduced drug susceptibility.

Efflux transporter: A parasite membrane protein that pumps antimalarial compounds out of the cell, lowering intracellular drug concentration.

Sequestration: The adherence of infected erythrocytes to microvascular endothelium, contributing to severe disease and influencing drug access.

References

1. Novel Therapeutics for Malaria. Pharmaceutics (2023).
2. A Chemical Proteomics Approach for the Search of Pharmacological Targets of the Antimalarial Clinical Candidate Albitiazolium in Plasmodium falciparum Using Photocrosslinking and Click Chemistry. PLOS ONE (2014).
3. Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination. F1000Research (2018).
4. Drug Development Strategies for Malaria: With the Hope for New Antimalarial Drug Discovery—An Update. Advances in Medicine (2023).